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Antibodies to blood group antigens can cause immune RBC
destruction directly (extravascular destruction) or indirectly
through subsequent complement activation (intravascular
hemolysis). The Fc portion of the IgG antibody is responsible for
the effector functions of immune RBC destruction. We
hypothesized that sensitization of RBCs with blood group
antigen–specific IgG antibodies lacking their Fc portion would
escape from the recipient’s immune system, allowing for a longer
survival period of the RBCs in the circulation. Direct injection of
mouse RBC-specific Ter-119 monoclonal antibody into mice
resulted in a more severe anemia compared with that in mice
injected with the Ter-119 F(ab´)2 fragment. We found that mouse
RBCs coated in vitro with the Ter-119 F(ab´)2 fragment, when
transfused into mice, survived longer in circulation compared with
RBCs coated with whole Ter-119 IgG molecule. The data support
the conclusion that antibodies can be rendered less pathogenic
through removal of their Fc portion. Immunohematology
2006;22:11–14.
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Alloantibodies and autoantibodies to blood group
antigens can cause immune RBC destruction, resulting
in transfusion reactions and autoimmune hemolytic
diseases.1 Antibodies to human glycophorin A
(GPA)–associated antigens can cause hemolytic
transfusion reactions and HDN.2 Ter-119, a rat IgG2b
monoclonal antibody, is a mouse erythroid-specific
antibody that recognizes GPA3 and causes autoimmune
hemolytic anemia after injection into mice.4 This
indicates that the Ter-119 antibody pathogenicity is
analogous to that of human GPA antibodies. Because
the Fc portion of the antibody molecule mediates its
effector functions, including binding to Fc receptors
and complement components,5 we hypothesized that
blood group–specific antibodies would be rendered
nonpathogenic by removal of their Fc domains. We
chose to use the F(ab´)2 fragment as compared with
the monovalent Fab fragment because of its higher
binding affinity (avidity) for the target antigens.
Although the use of antibody fragments directed
against a variety of antigens has been described, there
have been only two published studies that addressed
their in vivo application for antibodies directed against
RBC antigens. Specifically, in two previous reports, the
in vivo effects of F(ab´)2 prepared from anti-D were
compared to whole IgG but conflicting results had
been obtained.6,7 In one report, the antibody fragment
preparation resulted in complete clearance of D+
RBCs,7 whereas in the other report, only about one-
third of the RBCs were destroyed.6 The explanation
given for these unexpected results was that the
antibody fragment preparations used for the studies
had different degrees of contamination with intact IgG
molecules, which were responsible for RBC
destruction.
In this study, we compared the in vivo effects of
intact Ter-119 antibody with those of a highly purified
preparation of its F(ab´)2 fragment. We found that
direct injection of Ter-119 antibody into mice resulted
in a more severe anemia compared with that observed
in mice injected with the F(ab´)2 fragment. In addition,
mouse RBCs sensitized in vitro with the Ter-119
F(ab´)2 fragment exhibited prolonged survival in vivo
as compared with RBCs coated with the whole IgG
molecule.
Materials and Methods
Injection of antibodies into mice 
Ter-119 whole IgG and its F(ab´)2 fragment were
purchased (BD Pharmingen, San Diego, CA). Ter-119
F(ab´)2 fragment had approximately 1 percent IgG
contamination as determined by SDS-PAGE and HPLC
analysis (data not shown). Eight to 10-week-old
C57BL/6 mice were injected intraperitoneally with
nonagglutinating doses of Ter-119 whole IgG molecule
or its F(ab´)2 fragment. Blood samples (25 µl) were
obtained by retro-orbital sinus bleeding at the time
points indicated after antibody injection and whole
blood count was performed on the samples using Advia
120 Hematology System (Bayer,Tarrytown, NY).
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Transfusion of antibody-sensitized RBCs into mice 
Mouse RBCs were opsonized in vitro with Ter-119
or its F(ab´)2 fragment by incubating 1 × 109/mL RBCs
with various nonagglutinating concentrations of
antibody for 30 minutes at 37°C (data not shown). The
sensitized RBCs were checked by flow cytometry using
a FITC-conjugated goat anti-rat IgG (Vector
Laboratories, Burlingame, CA) to ensure uniform
coating of all RBCs. In addition, the percentage of
antigen sites that were occupied by the antibodies was
measured by flow cytometry using a PE-conjugated Ter-
119 antibody (BD Pharmingen). After they were
labeled with PKH-26 (Sigma, St. Louis, MO) according
to manufacturer’s instructions, the antibody-coated
RBCs were injected by the tail vein into 8- to 10-week-
old C57BL/6 female mice. Blood samples were
obtained by retro-orbital sinus bleeding at the time
points indicated after transfusion and the clearance of
fluorescent RBCs was measured by flow cytometry as
previously described.8 Ter-119 sensitization levels on
the transfused RBCs were determined by two-color
flow cytometry using FITC-conjugated rabbit anti-rat
IgG heavy and light chains (Vector Laboratories)
adsorbed to prevent any cross-reactivity with mouse
immunoglobulins. We also checked the transfused
RBCs for possible sensitization with mouse C3, IgG, or
IgM components by flow cytometry but none were
detected (data not shown).
Statistical analysis
The significance of differences between groups of
mice was calculated using ANOVA; only p values less
than 0.05 were considered significant.
Results
In a previous study by Jordan et al., it was shown
that nonagglutinating doses of Ter-119 antibody caused
anemia when injected into mice and that RBC
destruction was mediated by erythrophagocytosis by
splenic macrophages.4 To compare the ability of RBC-
specific Ter-119 antibody and its F(ab´)2 fragment to
cause anemia, C57BL/6 mice were directly injected
with either whole IgG molecule or its F(ab´)2
fragment. After a single injection of the antibodies at a
nonagglutinating concentration (80 µg) in both groups
of mice, all circulating RBCs of the mice were
sensitized with the injected antibodies (Fig. 1A). In
mice injected with the Ter-119 F(ab´)2 fragment, there
was a slight decrease in the Hb levels of all treated mice
(n = 4) over a 24-hour period (Fig.1B). In contrast,after
injection of an equivalent amount of whole IgG Ter-119
antibody, one of four mice was dead by 8 hours
postinjection and the other three had developed
anemia. By 24 hours postinjection, only one mouse
was alive and it had severe anemia (Fig. 1B). When we
injected a lower concentration of the whole IgG Ter-
119 (50 µg), all treated mice (n = 4) survived but
developed anemia (Hb levels of 8 ± 1.2 g/dL at 24 h
postinjection). These data indicate that the F(ab´)2
fragment of Ter-119 is less pathogenic than the whole
antibody molecule and that anemia caused by the RBC-
specific Ter-119 antibody can be reduced by removal of
its Fc portion.
We next opsonized equivalent numbers of mouse
RBCs in vitro with different nonagglutinating
concentrations (7 µg/mL, 5 µg/mL, or 3 µg/mL) of
either Ter-119 or its F(ab´)2 fragment and injected them
into C57BL/6 mice. RBCs opsonized in vitro with 7
µg/mL or 5 µg/mL of the whole IgG Ter-119 antibody
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Fig. 1. Direct injection of Ter-119 whole IgG and its F(ab´)2 fragment
into mice. (A) A representative flow cytometric analysis of RBCs
bled from C57BL/6 mice that had been injected with 80 µg Ter-
119 whole IgG or F(ab´)2 fragment at 8 hours postinjection using
a goat anti-rat secondary antibody, demonstrating that all
circulating RBCs were coated with the antibodies. RBCs from
mice not injected with antibody (“Normal”) were used as a
control. (B) Mice were bled 8 and 24 hours after injection of 
80 µg of the Ter-119 antibody (whole IgG or F[ab´]2 fragment) in
order to determine blood Hb concentration. Control mice (n =
4) were not injected with antibody (where n is the number of
animals per group). One of four mice injected with Ter-119
whole IgG died by 8 hours postinjection and another two were
dead by 24 hours. None of the mice (n = 4) injected with Ter-119
F(ab´)2 fragment died. Data are presented as means ± standard
errors.
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Prolonged RBC survival with F(ab´)2
were found to be rapidly cleared from the circulation
so that by 5 hours posttransfusion only about 20
percent of these RBCs remained in circulation (Fig. 2A
and 2B). In contrast, RBCs that were opsonized with
similar concentrations of the F(ab´)2 fragment were
only slightly reduced in numbers compared with
control, nonopsonized RBCs (Fig. 2A and 2B). Even at
lower (3 µg/mL) antibody concentrations, the Ter-119
coated RBCs were cleared more rapidly than those
opsonized with similar concentrations of the F(ab´)2
fragment (Fig. 2A). To ensure that the improved in vivo
survival of transfused F(ab´)2 -coated RBCs was not due
to differences in the levels of antibody sensitization,we
measured relative antibody levels on the transfused
RBCs and found comparable levels of antibody coating
on the circulating RBCs of both groups of mice (Fig.
2B). Thus, RBCs opsonized with the Ter-119 F(ab´)2
fragment have a higher survival in vivo than whole
IgG–sensitized RBCs.
Discussion
We have shown that RBC destruction by the RBC-
specific Ter-119 antibody can be reduced by removal of
its Fc portion. In addition, we demonstrated that RBCs
opsonized with the F(ab´)2 fragment of the Ter-119
antibody have a higher survival in vivo than RBCs
opsonized with similar concentrations of whole IgG
molecule. Although the protective effects of antibody
fragments in vivo for RBC survival have been
previously investigated, the results obtained were
confounded by the contamination of their antibody
fragment preparation with intact IgG.6,7 Our
experiments were performed with an F(ab´)2 fragment
preparation that was about 99 percent pure.
Altogether, the data are consistent with the concept
that the Fc portion of the antibody fragment mediates
RBC destruction.
The data suggest that antibody fragments lacking
the Fc portion may be used to escape recognition from
the recipient immune system, although future studies
are needed to assess the survival of F(ab´)2-coated
RBCs in mice that have preexisting antibodies. There is
precedent for masking target antigens using F(ab´)2
fragment. For example, direct injection of F(ab´)2
fragment with specificity against human platelet
antigens to patients with certain thromboembolic
disorders induces dose-related inhibition of platelet
aggregation by blocking the target antigen.9 Although
it remains to be tested, the data suggest that antibody
fragments may have potential for masking blood group
antigens to prevent antibody-mediated RBC
destruction. In the future, using the transfusion
protocols described here, we hope to test this
possibility by directly injecting F(ab´)2 fragments or
Ter-119 F(ab´)2-coated RBCs into mice with preexisting
Ter-119 antibodies and measuring RBC survival.
Fig. 2. Survival of transfused RBCs, opsonized in vitro with Ter-119
whole IgG or its F(ab´)2 fragment, in mice. RBCs were opsonized
in vitro with different concentrations of Ter-119 or its F(ab´)2
fragment. Although all the RBCs were uniformly coated with all
antibody concentrations tested, these antibody concentrations
were nonsaturating and at 5 µg/mL antibody dose used to coat
RBCs, about 50 percent of the target antigenic sites were still
reactive with a fluorescently labeled Ter-119 antibody (data not
shown). Following labeling with fluorescent dye PKH-26, the
RBCs were injected intravenously at a final Hct of 25% in 200 µL
into C57BL/6 mice. At times indicated, venous blood was
sampled and analyzed by flow cytometry for the fraction of
fluorescent RBCs. To show the clearance kinetics, injected RBCs
at 1 minute posttransfusion were taken as 100 percent and the
remaining RBCs were calculated at different time points as the
average for each group of mice. Error bars depict the standard
error of the mean (SEM). Survival of transfused RBCs opsonized
in vitro with (A) 7 µg/mL,5 µg/mL,and 3 µg/mL of Ter-119 whole
IgG or Ter-119 F(ab´)2 fragment in mice. Control (n = 7) mice
were injected with an identical number of dye-labeled, but not
opsonized, RBCs. Ter-119 whole IgG coated RBCs had lower
survival rates at all concentrations tested over a 24-hour period
(p < 0.05 as compared to control). The level of antibody coating
of the transfused RBCs opsonized in vitro with (B) 7 µg/mL, 5
µg/mL, and 3 µg/mL of Ter-119 whole IgG or Ter-119 F(ab´)2
fragment was measured by flow cytometry using a FITC-
conjugated anti-rat IgG at indicated times posttransfusion and is
presented in fluorescence intensity units on the y-axis as the
average for each group of mice (error bars depict the SEM). As
expected, the secondary antibody did not react with control,
nonopsonized, transfused RBCs.
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